{
  "subset": "indication",
  "disease": "Primary lymphoedema",
  "relation": "indication",
  "gold_drugs": [
    "chemotherapy"
  ],
  "seeds_initial": [
    "Doxycycline",
    "Sirolimus",
    "Tadalafil",
    "Pentoxifylline",
    "Benzopyrone",
    "Propranolol",
    "Rivaroxaban",
    "Diuretics",
    "Corticosteroids",
    "Sodium chloride",
    "Vasodilators",
    "Albendazole"
  ],
  "seed_history": [
    [
      "Doxycycline",
      "Sirolimus",
      "Tadalafil",
      "Pentoxifylline",
      "Benzopyrone",
      "Propranolol",
      "Rivaroxaban",
      "Diuretics",
      "Corticosteroids",
      "Sodium chloride",
      "Vasodilators",
      "Albendazole"
    ]
  ],
  "final_report": {
    "final_recommendations": [
      {
        "hypothesis_id": "H1",
        "candidate": {
          "id": "drug_doxycycline",
          "name": "Doxycycline"
        },
        "score": 0.76,
        "graph_snapshot_ref": "GE_H1_round5",
        "key_assumptions": [
          "MOA→淋巴系统→淋巴调节通路链闭合",
          "PK/BBB 可达性足够"
        ],
        "caveats": [
          "安全性与长期疗效不明"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H2",
        "candidate": {
          "id": "drug_sirolimus",
          "name": "Sirolimus"
        },
        "score": 0.75,
        "graph_snapshot_ref": "GE_H2_round5",
        "key_assumptions": [
          "MOA→淋巴系统→淋巴调节通路链闭合",
          "PK/BBB 可达性足够"
        ],
        "caveats": [
          "安全性与长期疗效不明"
        ],
        "confidence": "medium"
      }
    ],
    "audit_report": {
      "decisive_graph_motifs": [
        {
          "pattern": "Drug→Lymphatic System→Lymphatic Regulation Pathway→Primary Lymphoedema",
          "reason": "机制闭环且有不相交备援路径"
        }
      ],
      "remaining_gaps": [
        "冲突热点的短期/长期效应差异未消解"
      ]
    },
    "seed_retrospective": {
      "batches": [
        {
          "round": 1,
          "seeds": [
            "A",
            "B",
            "C",
            "D"
          ],
          "impact_summary": "补齐了通路 X，path_disjointness↑"
        },
        {
          "round": 2,
          "seeds": [
            "E",
            "F"
          ],
          "impact_summary": "安全性冲突仍高，建议剪枝"
        }
      ],
      "lessons": [
        "安全性主导的负面分值，需引入人群/PK 友好的替代类别",
        "当机制连通性普遍缺失时，优先引入作用位点/通路不同的候选"
      ]
    },
    "prompt_patches": [
      {
        "role": "Proponent",
        "patch": "优先构造≥2条不相交的机制路径；合并同义机制节点，减少稀释。"
      },
      {
        "role": "Skeptic",
        "patch": "对安全性主题给出可证伪的最小事实点，并用高权重 refutes 边显式标注。"
      },
      {
        "role": "Explorer",
        "patch": "保持与 query.entity/relation 一致；去重；优先覆盖新的作用机制/组织定位；避免重复已存在候选。"
      }
    ],
    "heuristics": []
  },
  "experience_used": true,
  "explorer_prompt": "List drugs that could be indicated for the rare disease 'Primary lymphoedema'. Return only names.\n\n# Heuristics:\n- When 淋巴水肿表型: then 重点关注药物引起的不良反应，确保有效性与安全性并重"
}